New PALFORZIA™ Data on Long-Term Safety, Efficacy and Immunomodulation and New Data on Patient Satisfaction with PALFORZIA Treatment to be Presented at EAACI 2020 Congress

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for life-threatening food allergies, today announced it will present important new long-term safety, efficacy and immunological data from ARC004, an open-label, rollover study of the landmark pivotal PALISADE trial of PALFORZIA™ [Peanut (Arachis hypogaea) Allergen Powder-dnfp] and data on patient-reported treatment satisfaction from the European phase 3 ARTEMIS trial of PALFORZIA. In addition, insights from the PAPRIQUA study about the psychosocial burden of peanut allergy on children and their caregivers will be presented. These data will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress to be held from June 6-8.